Cargando…
Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines
[Image: see text] Human epidermal growth factor receptor 2 (HER2) is overexpressed in nearly 20–30% of breast cancers and is associated with metastasis resulting in poor patient survival and high recurrence. The dual EGFR/HER2 kinase inhibitor lapatinib has shown promising clinical results, but its...
Autores principales: | Schroeder, Richard, Sfondouris, Mary, Goyal, Navneet, Komati, Rajesh, Weerathunga, Achira, Gettridge, Cory, Stevens, Cheryl L. Klein, Jones, Frank E., Sridhar, Jayalakshmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648266/ https://www.ncbi.nlm.nih.gov/pubmed/31460159 http://dx.doi.org/10.1021/acsomega.9b00929 |
Ejemplares similares
-
Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014) -
Ligands of Therapeutic Utility for the Liver X Receptors
por: Komati, Rajesh, et al.
Publicado: (2017) -
Coumarins and P450s, Studies Reported to-Date
por: Foroozesh, Maryam, et al.
Publicado: (2019) -
Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date
por: Sridhar, Jayalakshmi, et al.
Publicado: (2017) -
Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies
por: Sridhar, Jayalakshmi, et al.
Publicado: (2012)